Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects

Research output: Contribution to journalReviewpeer-review

DOI

  1. Understanding the relationship between cognitive performance and function in daily life after traumatic brain injury

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dependence-like behaviour in patients treated for medication overuse headache: A prospective open-label randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comparison of 3 Treatment Strategies for Medication Overuse Headache: A Randomized Clinical Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia

    Research output: Contribution to journalReviewpeer-review

  • Jason Charles Ray
  • Mahima Kapoor
  • Richard J Stark
  • Shuu-Jiun Wang
  • Lars Bendtsen
  • Manjit Matharu
  • Elspeth Jane Hutton
View graph of relations

Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.

Original languageEnglish
JournalJournal of neurology, neurosurgery, and psychiatry
ISSN0022-3050
DOIs
Publication statusE-pub ahead of print - 2021

    Research areas

  • drug trials, headache, migraine

ID: 62004232